These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 14682224

  • 41. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, Brock F, Franck-Larsson K.
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [Abstract] [Full Text] [Related]

  • 42. [Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].
    Bertin P, Carpentier N, Vergne P, Bonnet C, Bannwarth B, Dehais J, Treves R.
    Therapie; 1997 Jan; 52(2):133-7. PubMed ID: 9231508
    [Abstract] [Full Text] [Related]

  • 43. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E, Kageyama Y, Takahashi M, Nagano A.
    Mod Rheumatol; 2006 Jan; 16(6):350-4. PubMed ID: 17164995
    [Abstract] [Full Text] [Related]

  • 44. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M, Schettler JD, Fries JF.
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [Abstract] [Full Text] [Related]

  • 45. Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy.
    Králícková P, Melichar B, Malír F, Roubal T.
    J Exp Clin Cancer Res; 2004 Dec; 23(4):579-84. PubMed ID: 15743027
    [Abstract] [Full Text] [Related]

  • 46. Renal effects of low dose methotrexate in rheumatoid arthritis.
    Seideman P, Müller-Suur R, Ekman E.
    J Rheumatol; 1993 Jul; 20(7):1126-8. PubMed ID: 8371203
    [Abstract] [Full Text] [Related]

  • 47. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL, Mader RM, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Kalipciyan M, Jilma B.
    Clin Exp Rheumatol; 2011 Jul; 29(6):963-9. PubMed ID: 22133036
    [Abstract] [Full Text] [Related]

  • 48. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 49. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Asymptomatic primary hyper- N-acetyl-beta-D-glucosaminidaseuria: a new clinical entity?
    Asami T, Soichiro O, Kasahara T, Uchiyama M.
    Pediatr Nephrol; 2002 Jul; 17(7):560-5. PubMed ID: 12172776
    [Abstract] [Full Text] [Related]

  • 52. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB, von Kempis J, Haile SR, Schiff MH.
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [Abstract] [Full Text] [Related]

  • 53. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?
    Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, Kevat S.
    J Rheumatol; 1988 Sep; 15(9):1356-60. PubMed ID: 3199396
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK.
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease.
    Kunin CM, Chesney RW, Craig WA, England AC, DeAngelis C.
    Pediatrics; 1978 Nov; 62(5):751-60. PubMed ID: 364392
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort.
    Gaujoux-Viala C, Paternotte S, Combe B, Dougados M.
    Rheumatology (Oxford); 2012 Sep; 51(9):1648-54. PubMed ID: 22661552
    [Abstract] [Full Text] [Related]

  • 60. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M, Kotaska K, Kukacka J, Vavrova V, Kuzelova M, Ticha J, Prusa R.
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.